The abundance of tumor-infiltrating CD4+ T cells was increased by 3–12-fold over the saline control in the GSC005 tumor and peaked around day 14 post-M002 treatment in both GBM models (Fig. 2a and Supplementary Fig. 3a). The gene discussed is CD4; the disease is glioblastoma.